Compare Gold Fields Limited (GFI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Spyre Therapeutics Inc. Common Stock — how do they compare? Gold Fields Limited trades at $36.68 (market cap $32.51B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Gold Fields Limited is far larger — about 4.3× Spyre Therapeutics Inc. Common Stock's market cap, and Gold Fields Limited pays a 5.92% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 50 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GFI | SYRE | |
|---|---|---|
Market Cap | $32.51B | $7.52B |
Volume | 3,490,155 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $108.92 |
52-Week Low | $31.25 | $22.18 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $33.11B | $6.52B |
Dividend Yield | 5.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.55, down 3.29% amid market reaction to its rejected $27 billion bid for Northern Star. Despite recent earnings misses, the company shows strong fundamentals with a low P/E of 7.4, robust net income margin of 38.66%, and record 2025 revenue of $8.75 billion. Technical indicators are bearish, with the stock near key support at $36. Analyst consensus remains positive with a $52.75 price target, though sentiment is cautious due to acquisition uncertainty.
The outlook for GFI is mixed; its undervalued metrics and high profitability support upside potential, but near-term volatility from the failed acquisition and bearish technicals pose risks. Investors should weigh the company's strong cash flow generation and growth prospects against execution risks and gold price sensitivity.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
